XM does not provide services to residents of the United States of America.
T
T

ThermoFisher

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Agilent reports better-than-expected first quarter results, shares rise

Agilent reports better-than-expected first quarter results, shares rise Feb 27 (Reuters) - Agilent Technologies A.N on Tuesday beat Wall Street estimates for first-quarter profit and revenue, helped by strong sales in its life sciences and diagnostics units, sending shares up 5% in extended trading. The equipment maker reported quarterly revenue of $1.66 billion, which was above analysts' estimates of $1.58 billion, according to LSEG data.
A
T

IQVIA quarterly results beat estimates on strong demand for research services

IQVIA quarterly results beat estimates on strong demand for research services Feb 14 (Reuters) - IQVIA Holdings IQV.N beat Wall Street estimates for fourth-quarter sales and profit on Wednesday, on the back of strong demand for its drug research and development services. Shares of IQVIA were up nearly 5% before the bell. IQVIA's quarterly results provide some relief about concerns of sluggish demand for contract research services as rising interest rates squeeze funding this year, prompting biot
T
I

Waters Corp beats Q4 sales estimates on strong demand for drug development services

Waters Corp beats Q4 sales estimates on strong demand for drug development services Feb 6 (Reuters) - Waters Corp WAT.N on Tuesday reported fourth-quarter sales ahead of Wall Street estimates, helped by demand for its services used in drug development. The lab equipment and software maker reported fourth-quarter sales of $819.5 million, beating analyst s' estimates of $815.03 million, according to LSEG data.
T
W

DocuSign's deal talks with Bain, Hellman & Friedman stall-sources

UPDATE 1-DocuSign's deal talks with Bain, Hellman & Friedman stall-sources Adds more background and details on DocuSign throughout By Milana Vinn and Anirban Sen Feb 5 (Reuters) - Bain Capital and Hellman & Friedman have cooled in their pursuit of DocuSign Inc DOCU.O over disagreements on how much they should pay to acquire the provider of online signature services, three people familiar with the matter said on Monday.
D
T
U
F
T

Novo Nordisk's parent to buy Catalent for $16.5 bln to boost Wegovy supply

UPDATE 6-Novo Nordisk's parent to buy Catalent for $16.5 bln to boost Wegovy supply Adds investor comment in paragraph 12 By Maggie Fick and Patrick Wingrove Feb 5 (Reuters) - Novo Nordisk NOVOb.CO notched a win on Monday in its race to boost output of its popular obesity drug Wegovy, with its parent company announcing it was buying Catalent CTLT.N , a key manufacturing subcontractor of the product, for $16.5 billion.
T

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.